Today's deal net contains news from Boston Metal, Evologic Therapeutics, Lilz, GaitQ, Hemerion Therapeutics and Rebrain.

Female-focused venture firm Astia has secured Mastercard as lead investor for its recently-launched early-stage fund.

The share price of Columbia University's cellular oncology drug developer, backed by Osage University Partners, has doubled since it floated.

The 'front page of the internet' raised the money in a Vy Capital-led round doubling its valuation to $6bn, up from a Tencent-led round two years ago.

The share price of the cellular oncology drug developer, which counts Novartis, Johnson & Johnson and PureTech Health as investors, has doubled since it floated.

Nagraj Kashyap is leaving his position as head of Microsoft's M12 subsidiary to take up a managing partner role overseeing SoftBank's Vision Funds.

The Eli Lilly-backed liver disease drug developer floated at the top of its range to raise almost $128m, following $207m of venture funding.

Trilantic North America and Energy Impact Partners provided the capital for the Shunfeng Photovoltaic-backed energy storage technology producer.

Today's deal net contains news from Nexthink, Metalenz, Grapheal, CellulaRevolution and Astrata.

The autonomous driving technology provider has added series C-plus funding to a $376m FAW-backed round in November valuing it above $5bn.